Introduction {#S1}
============

The development of the organoid methodology counts today as a major technological breakthrough in stem cell research. It enabled immense advances in the application of human induced pluripotent stem cells (hiPSCs) and was even celebrated as the "Method of the Year" in 2017 ("[@B71]").

Cerebral Organoids {#S2}
==================

Initial experiments on self-organization of PSCs under 3D conditions were performed more than 10 years ago. Yet, it were the findings of Lancaster et al., that actually launched a new era in research on the human brain by introducing the "cerebral organoids" in 2013 ([@B71]; [@B61]). Supporting the conclusions of initial 3D culture experiments, Lancaster et al. took advantage of the PSCs' intrinsic self-organization and derived neuroepithelium under 3D conditions ([@B58]). To avoid limitations on specific brain region identities, they did not add patterning growth factors. Instead, after aggregation, the cells were embedded in Matrigel, a surrogate matrix that was previously introduced for the generation of intestinal organoids ([@B103]). This serves as a structural support, inducing the correct polarity stimulus to promote the complex outgrowth of large, apicobasal neuroepithelial buds ([@B69]; [@B118]). These buds expand during the course of culture and acquire not only various brain identities but also fluid-filled lumina reminiscent of brain ventricles. To improve nutrient supply and oxygen exchange, the floating cerebral organoids were cultured in spinning bioreactors or on orbital shaker plates, allowing organoids to grow up to 4 mm in diameter ([@B69]; [@B61]). These optimized growth conditions combined with the intrinsic self-organizing capabilities of PSCs resulted in the formation of a variety of brain regions within a single organoid, including hindbrain, midbrain, forebrain, and even retinal tissue identities ([@B71]; [@B70]; [@B98]; [@B118]). Remarkably, a detailed study about the patterning events during the course of cerebral organoid development and differentiation indicates that spatial and temporal patterning events are reminiscent of those determining the human brain development ([@B98]).

Modification of Cerebral Organoids {#S3}
==================================

The classic cerebral organoid protocol, describing the generation of general whole-brain organoids, has been modified by many research groups in the last years and has resulted in the formation of more regionally specific 3D cell cultures ([@B69]; [@B68]). In the study of [@B90]), both bone morphogenetic protein (BMP) and transforming growth factor β (TGF-β) signaling pathways were inhibited by the small molecules Dorsomorphin (DM) and SB-431542 (SB) to achieve an effective neural induction. This dual-SMAD inhibition, in combination with fibroblast growth factor (FGF) 2, epidermal growth factor (EGF) and the absence of extracellular scaffolding, gave rise to neural progenitors expressing the dorsal telencephalic markers paired box protein 6 (PAX6) and forkhead box protein G1 (FOXG1). Further neuronal differentiation was promoted by replacing FGF2 and EGF with brain-derived neurotrophic factor (BDNF) and neurotrophic factor 3 (NT3) and led to the generation of various neural and glial identities of the dorsal cortex within each spheroid, including superficial and deep cortical layer neurons ([@B90]; [@B61]). With this, Paşca et al. described a method that gave rise to a 3D culture specific of a brain subregion; a culture that exhibited a reduced number of ectodermal derivatives compared to the original cerebral organoid protocol. A similar approach of using a dual-SMAD inhibition was published by [@B93]. While maintaining the basis of the [LANCASTER]{.smallcaps} protocol, such as Matrigel embedding and agitation, they demonstrated that it is possible to culture organoids in 3D printed miniaturized bioreactors, thus enabling more feasible, scaled-up productions of neural 3D cultures ([@B93]). Another advantage of the self-engineered multi-well spinning device is the possibility of comparing numerous different culture conditions in parallel. Paşca et al. aimed to reduce the tissue heterogeneity of the cerebral organoids and therefore pre-patterned the embryoid bodies (EBs) to obtain specific brain regions. The inhibition of TGF-β signaling by SB and activation of Wnt signaling by glycogen synthase kinase 3 (GSK-3β) inhibitor CHIR-99021 (CHIR) within the first 2 weeks of culture, resulted in forebrain organoids organized in defined, multi-layered progenitor zones, including homologs to the ventricular zone (VZ), the inner and outer subventricular zones (SVZ). Moreover, neuronal types of all six cortical layers could be detected within these forebrain-specific organoids. With the help of the mini-bioreactors, [@B93] also developed a method to derive hypothalamic-specific organoids. After a dual-SMAD inhibition with SB and LDN-193189 (LDN), they patterned the neuroectodermal cells to a hypothalamic fate by activating Wnt and sonic hedgehog (SHH) signaling, applying WNT3a, SHH, and Purmorphamine (PMA) to the culture. 40 days later, these organoids contained cell populations expressing markers specific of hypothalamic neuronal lineages ([@B93]).

Disease Modeling With Brain Organoids {#S4}
=====================================

Similar characteristics on a molecular, cellular and physiological basis between human brain organoids and the actual human brain justify their increasing application in studying brain biology and modeling neurological disorders ([@B119]). Already [@B71] discovered the potential of cerebral organoids as a model to detect impaired neurodevelopment and they derived organoids carrying a mutation that causes microcephaly. It was also suggested that a Zika virus (ZIKV) infection was causing microcephaly in neonates. In 2016, the World Health Organization (WHO) declared the ZIKV and its associated complications an emergency of public health ([@B93]; [@B36]). This activation of the global research community led to an accelerated development of vaccines and treatments, with many studies based on cerebral organoids, which were able to recapitulate features of human cortical development *in vitro* ([@B28]; [@B30]; [@B40]; [@B81]; [@B87]; [@B93]; [@B120]; [@B122]). The results of these studies indicate that a ZIKV infection affects the neurogenesis, disrupts the cortical layers of the organoids, and, in a similar manner, causes microcephalic-like deficits in cortical development ([@B36]). Due to the specific embryonic formation of human brains, only a human-specific 3D cell culture model exhibiting advanced organizational features could have led to the reported discoveries. Neither murine nor 2D cell culture were able to address the potential link between ZIKV and microcephaly ([@B93]; [@B36]; [@B107]). In addition to this successful application, brain organoids have proven useful to study other neurological disorders. Recently, so-called "tumouroids" have been established from human glioblastoma, the most common and aggressive brain cancer ([@B36]). The hypoxic gradients and stem cell heterogeneity found in these tumouroids cannot be recreated via conventional culture methods. Therefore, glioblastoma organoids offer a unique opportunity for their application in brain cancer diagnostics and therapeutics ([@B51]; [@B36]; [@B8]). Furthermore, two different approaches using 3D human neural cell culture systems were reported to recapitulate Alzheimer's disease (AD) phenotypes *in vitro* ([@B22]; [@B95]). These 3D cultures provide an environment that promotes the formation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs), pathological events that could not have been serially linked before by using 2D cultured human neurons ([@B22], [@B23]; [@B31]; [@B95]). This confirms that the evolving brain organoid methodology facilitates the development of more precise human cellular models that can support the research of neurodegenerative disorders. The technology of more complex 3D cell culture systems not only bridges the gap between traditional 2D *in vitro* experiments and *in vivo* animal models, but also addresses processes that cannot be recapitulated by these traditional models. For example, drug failure or unanticipated side-effects upon translation to humans can be a result of the different metabolisms of humans and animals. Therefore, human organoids offer an opportunity to unravel complex biological processes, such as the development of the human brain, where conventional models have not proven successful. The establishment of stem cell-derived brain organoids allows the modeling of key aspects of human brain development *in vitro*, by utilizing the enormous differentiation potential of PSCs and their ability to self-organize with a specific spatial orientation. Overall, this novel technology provides a physiologically relevant context, such as interactions between glia cells and neurons in a spatially organized microenvironment, which holds great potential for its application in modeling neurological diseases.

Discussion {#S5}
==========

The lack of advanced experimental *in vitro* models that truly recapitulate the complexity of the human brain is one of the main limitations in neuroscience and in the field of disease modeling. Current *in vitro* approaches to model physiology and pathology of human neurons are primarily based on cultures of neurons grown under 2D conditions. While the resulting monolayer cell cultures have proven useful as a tool to study disease mechanisms and to identify potential neuroprotective compounds ([@B85]; [@B27]; [@B101]; [@B97]; [@B100]; [@B94]; [@B111]), these culture conditions do not model several characteristics which are relevant to the human brain. Features such as cell-cell interactions and cytoarchitecture might be crucial to predict the effectiveness of *in vitro* tested compounds in clinical trials ([@B1]). In this case, the *in vitro* human brain organoid technology is a valuable tool, it allows to opportunity to understand complex biology in a physiologically relevant context and also enables advances in translational applications ([@B38]). Originally, brain organoid approaches relied on the endogenous capacity of PSCs to self-organize under 3D conditions, intrinsically following early steps of the brain development ([@B4]). These approaches resulted in ectodermal derivatives with complex cytoarchitectures beyond what is possible with 2D PSC derivatives ([@B58]; [@B71]; [@B90]). Since neurons form functional networks with other neurons and non-neuronal cells in the brain, it is essential to expand the research of neurodegenerative diseases by exploiting 3D models that are able to reproduce these interactions. In general, 3D conditions are able to more closely mimic *in vivo* environments and therefore enable an accelerated neuronal differentiation and network formation *in vitro* ([@B48]; [@B31]). Moreover, it has been shown that neurons developed in a 3D environment express a more representative range of neuronal genes than neurons derived in 2D conditions ([@B105]). A monolayer of neurons cannot provide as many connections between individual cells as a 3D neuronal culture, and the smaller synaptic distances in a 3D neuronal network promotes functional signal transduction ([@B29]; [@B31]). By creating a third dimension, neurons develop in an environment that is closer to nature and actually relevant to human physiology, consequently gaining morphological and physiological properties similar to those *in vivo*.

Specifically, the generation and characterization of a novel midbrain-specific 3D cell culture system provides an advanced *in vitro* model to study neurodevelopmental processes as well as neurodegenerative diseases of the human midbrain. In order to achieve the formation of these highly specialized structures, distinctively resembling the human midbrain, organoids have been derived from regionally patterned neural stem cells (NSCs). This particular starting population, already committed to the ventral neural tube fate of the mesencephalon with further application of spatio-temporal specific signaling under 3D culture conditions, has led to the establishment of novel human midbrain-specific organoids (hMO). Here, we compare and evaluate newly derived hMO methods that create a powerful tool for human-specific *in vitro* disease modeling of neurological disorders.

Derivation of Midbrain-Specific Organoids {#S6}
=========================================

To achieve the *in vitro* derivation of the human midbrain, additional stimuli of specific pathways along with the 3D PSC culture are required. To date, six 3D cell culture approaches have been published by different research groups for deriving tissue that resembles features of the human midbrain ([@B116]; [@B57]; [@B93]; [@B83]; [@B62]; [@B110]). All of these approaches can be attributed to previous 2D cell culture experiments, which explored the fundamental principles for the generation and characterization of midbrain fate-specific cells, derived from PSC via exogenous patterning cues ([@B67]; [@B63]; [@B96]). For instance, Qian et al. were inspired by 2D experiments performed by [@B67] and also initial midbrain-like tissue experiments reported by [@B116] and ([@B93]). In the same year, another protocol describing the generation of hMOs was published ([@B57]). [@B57] and later [@B62] based their derivation on the findings of [@B21]. Additionally, hMO protocols described by [@B83] and [@B110] are based on 2D experiments by [@B96].

The initial step for the derivation of hMOs is the formation of EBs and induction of the neuroectoderm via dual-SMAD inhibition. In all hMO protocols compared here, SB was used to inhibit the Activin/TGF-β signaling pathway ([Table 1](#T1){ref-type="table"}). The combination with BMP pathway inhibitors enabled a full neural conversion of the PSCs. The use of BMP antagonists Noggin, LDN, and DM has been shown in 2D ([@B21]; [@B67]; [@B96]) and applied in 3D stem cell cultures ([Table 1](#T1){ref-type="table"}). To control the specification of the neural progenitor cells, CHIR, a potent chemical inhibitor of GSK-3β, was used to dose-dependently activate the WNT signaling pathway ([@B63]). The final patterning, toward midbrain floor plate precursors, requires a treatment with small molecule activators of the SHH signaling pathway, such as recombinant SHH, PMA or smoothened agonist (SAG) ([@B67]; [@B110]). This composition of exogenous patterning cues results in neural progenitors that can give rise to authentic, midbrain-specific dopaminergic neurons (mDANs) ([@B67]; [@B63]; [@B34]; [@B86]).

###### 

Comparison of hMO derivation protocols: Overview of applied compounds to derive midbrain-specific neuralectoderm by neural induction.

                             **[@B116]**   **[@B93]**   **[@B57]**   **[@B83]**   **[@B62]**   **[@B110]**
  -------------------------- ------------- ------------ ------------ ------------ ------------ -------------
  **Dual-SMAD inhibition**                                                                     
  SB                         10 μM         10 μM        10 μM        10 μM        10 μM        10 μM
  Noggin                     --            --           200 ng/ml    --           200 ng/ml    --
  LDN                        100 nM        100 nM       --           --           --           150 nM
  DM                         --            --           --           1 μM         --           --
  **WNT activation**                                                                           
  CHIR                       3 μM          3 μM         3 μM         3 μM         3 μM         3 μM
  **SHH activation**                                                                           
  SHH                        100 ng/ml     100 ng/ml    100 ng/ml    --           100 ng/ml    --
  PMA                        2 μM          2 μM         --           0.5 μM       --           --
  SAG                        --            --           --           --           --           0.5 μM
  **FGF8 activation**                                                                          
  FGF8                       100 ng/ml     100 ng/ml    100 ng/ml    --           100 ng/ml    --

hMO protocols from

Tieng et al. (2014)

and

Qian et al. (2016)

are based on 2D experiments by

Kriks et al. (2011)

; hMO protocols from

Jo et al. (2016)

and

Kim et al. (2019)

are based on 2D experiments by

Chambers et al. (2009)

; hMO protocols from

Monzel et al. (2017)

and

Smits et al. (2019b)

are based on 2D experiments by

Reinhardt et al. (2013a)

.

The further development of these protocols allowed the derivation of 3D cultured hMO. In contrast to 2D monolayer cultures, hMOs can recapitulate complex interactions of mDANs with other cell types of the central nervous system (CNS) in a 3D environment. Cluster analysis, comparing the differentially expressed genes of hMOs, 2D-cultured mDANs, and human prenatal midbrain samples indicated that hMOs share features of gene expression profiles of the prenatal midbrain, which cannot be recreated via the conventional 2D derivation method for mDANs ([@B57]). This demonstrates that the specific cellular structure and heterogeneity of the midbrain-specific organoid cultures allows biological aspects to be modeled, which cannot be mimicked with current 2D stem cell cultures. Additionally, enormous amounts of disease-relevant mDANs can be produced in a rapid and reproducible way, which is required for disease modeling and drug discovery in the field of Parkinson's disease (PD). Numerous published protocols describe the generation of ventral mDANs from human PSCs in 2D by replicating mDAN's *in vivo*-specification *in vitro* ([@B67]; [@B63]; [@B34]; [@B86]). Although current protocols are based on the generation of LMX1A/FOXA2 positive midbrain floorplate progenitors, differentiations starting from PSCs are time-consuming and typically result in cultures containing various neuronal identities ([@B47]; [@B67]; [@B63]; [@B45]). Typically, brain organoids are generated from PSCs by exploiting developmental processes ([@B71]; [@B26]) or by creating an environment favoring specific stem cell niches ([@B116]; [@B57]; [@B93]; [@B62]). However, the utilization of NSCs as a starting population for hMOs has the advantage that already patterned cells differentiate more efficiently into the desired structures. Other adult stem cell-derived organoid cultures have been established for instance, for the generation of intestinal or lung organoids. They contain cell types that are present in the organ from which they were derived and recapitulate some degree of its spatial organization ([@B25]; [@B52]; [@B35]). Similarly, the presence of midbrain-specific stem cell niches and clusters of mDANs was shown in a NSC-derived hMO model and approaches to efficiently differentiate mDANs within hMOs by starting from expandable neural precursor cells (NPCs) were reported ([@B83]; [@B109], [@B110]; [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). In these approaches NPCs that received already some patterning toward the midbrain have been used. Both hMO models have been already used in other studies ([@B6]; [@B55]; [@B56]). Among the published hMO protocols, different approaches have been presented to estimate the number of mDANs that arise during the organoid development ([Table 2](#T2){ref-type="table"}). [@B116] dissociated their 3D structures and cultured the resulting single cells as a monolayer ([@B93]). Their quantification resulted in more than 60% TH-positive cells in 21 day-old cultures ([@B116]) and around 55% TH-positive cells after 65 days ([@B93]). A more straightforward method to quantify the mDAN population is flow cytometry via fluorescence-activated cell sorting (FACS), which also requires dissociated hMOs. By doing so, it has been shown that after 61 days of culture around 64% cells were triple-positive for the mDAN markers TH, LMX1A, and FOXA2 ([@B83]). Surprisingly, with the same method, [@B57] identified only around 22% of MAP2-positive neurons co-expressing TH in their hMOs after 60 days of culture. A third approach to estimate the percentage of mDANs within hMOs has been described recently ([@B10]; [@B110]). Here, image analysis algorithms enabled the automated segmentation of nuclei and neurons, with around 62% TH-positive cells after 35 days and around 54% TH-positive cells after 70 days of 3D culture were quantified. The application of high-content image-analysis allows entire organoid sections to be examined, rather than dissociated single cells, which preserves the original morphology and cell-cell interactions of the mDANs. TH is a marker commonly used for mDAN detection, as it is a rate-limiting enzyme for DA biosynthesis. However, it is also expressed in other catecholaminergic cell types and does not represent a unique marker specifically for mDANs, as in the case of the dopamine transporter (DAT) for example or the actual presence of the neurotransmitter DA ([@B2]). DAT expression has been reported in almost every hMO model ([@B57]; [@B93]; [@B83]; [@B62]; [@B110]; [Table 2](#T2){ref-type="table"}).

###### 

Comparison of characteristics of different hMO derivation protocols: Overview of hMO-specific features reported in [@B116]; [@B57]; [@B93]; [@B83]; [@B62]; [@B110] (\*, different methods applied to determine and calculate TH content; °, different methods applied to determine DA content).

                          **[@B116]**   **[@B93]**   **[@B57]**   **[@B83]**   **[@B62]**   **[@B110]**
  ----------------------- ------------- ------------ ------------ ------------ ------------ -------------
  **mDANs**                                                                                 
  TH\*                    \>60% (d21)   55% (d65)    22% (d60)    64% (d61)    n/a          54% (d70)
  DAT                     n/a           Yes          Yes          Yes          Yes          Yes
  DA°                     Yes           Yes          Yes          Yes          Yes          Yes
  NM                      n/a           n/a          Yes          Yes          n/a          Yes
  **Glial cells**                                                                           
  Oligodendrocytes        Yes           n/a          Yes          Yes          n/a          n/a
  Astrocytes              Yes           Yes          Yes          Yes          n/a          n/a
  **Neuronal subtypes**                                                                     
  GABAergic               No            n/a          Yes          n/a          n/a          Yes
  Glutamatergic           Yes           n/a          n/a          n/a          n/a          Yes
  Serotonergic            No            n/a          n/a          n/a          n/a          Yes

###### 

Comparison of NSC-derived hMO models: Overview of selected features of hMOs approaches published in [@B83]; [@B110].

                              **[@B83]**     **[@B110]**
  --------------------------- -------------- --------------
  **Culture conditions**                     
  Used cell type              smNPCs         mfNPCs
  Number of cells             9,000          3,000
  Embedding                   Yes            No
  Agitation                   Yes            No
  **mDANs**                                  
  TH + cells\*                ∼64% (d61)     ∼54% (d70)
  Regionalization             Yes            No
  A9/A10 specificity          Yes            Yes
  DAT                         Yes (d61)      Yes (d70)
  D2/D3 receptor responsive   Yes            Yes
  DA release                  No             Yes
  NM                          Yes (\>d149)   Yes (\>d100)
  **Other cell types**                       
  Oligodendrocytes            Yes (d61)      n/a
  Astrocytes                  Yes (d61)      n/a
  Neuronal subtypes           n/a            Yes

Neuronal subtypes refers to the analysis whether neurons other than dopaminergic neuros are determined. As starting cell population, small molecule neural precursor cells (smNPCs) are used in

Monzel et al., 2017

, while

Smits et al. (2019b)

starts with midbrain floor plate neural progenitor cells (mfNPCs). \*, different methods applied to determine and calculate TH content.

[@B116] did not show the presence of DAT in their engineered nervous tissues (ENTs), but they were able to prove the synthesis of DA via high-performance liquid chromatography (HPLC) after cell lysis. Also [@B57] and [@B62] also applied the same method to assess the DA content within the hMOs. To verify that the mDANs were not only able to produce DA, but actually able to release the neurotransmitter, the supernatant of the 3D cultures can be analyzed with an enzyme-linked immunosorbent assay (ELISA). [SMITS]{.smallcaps} et al. detected a DA release that increased as the hMOs matured ([@B110]). An interesting observation was reported for the first time by [JO]{.smallcaps} et al., where they detected insoluble, dark-colored deposits in their hMOs after approximately 60 days ([@B57]). Using a Fontana-Masson staining they confirmed that these granules were neuromelanin (NM), which is a by-product of DA biosynthesis and accumulates postnatally in the *substantia nigra pars compacta* (SNc) of the human brain ([@B123]; [@B91]; [@B62]). Other hMO culture protocols have also stimulated the production of NM ([@B83]; [@B110]; [Table 2](#T2){ref-type="table"}). The presence of NM is a unique feature of the primate brain ([@B91]). It is neither apparent in mice brains nor murine midbrain-specific organoids ([@B39]; [@B32]; [@B57]; [@B77]). Wild-type mDANs, derived and cultured in monolayer conditions, only produce NM after an artificial inductions of progerin expression, which is associated with premature aging ([@B80]; [@B112]). Membrane-bound, dense pigmented NM was also detected in long-term cultures of homozygous DJ-1 mutant and idiopathic PD patient-derived mDANs ([@B15]). Currently, it is unknown whether NM has a protective or damaging effect on the cell survival, however, it is proven that NM-containing mDANs of the SNc are especially vulnerable during the course of PD ([@B123]; [@B57]; [@B77]). Therefore, NM containing hMOs have a great potential to be used for *in vitro* PD modeling, possibly revealing specific phenotypes that are not present in wild-type 2D cultures or murine models. Moreover, hMOs provide the basis for future studies about the role of NM in PD ([@B77]; [@B79]). Since mDANs are essential to model the human midbrain, hMO research has so far focused mainly on this specific type of neurons. Nevertheless, detailed *in vivo* studies have described that the released DA diffuses into synaptic regions of glutamatergic and GABAergic synapses and directly affects other striatal cell types, including the neurons forming the island-/striosome GABA pathway, striatal cholinergic interneurons and the striatal GABA interneurons, all possessing DA receptors ([@B18]; [@B11]). Furthermore, *substantia nigra* (SN) dopaminergic neurons are directly controlled by GABAergic input ([@B114]). Evidence from these studies suggest that the presence of other neuronal subtypes is important to be able to model multifactorial disease like PD. A first transcriptional characterization of hMO was performed by [@B57], showing that aspects of prenatal midbrain gene expression profiles were found in the organoids in contrast to the conventional 2D-derived mDANs ([@B115]; [@B73]). For a further validation of the genetic expression profile during the course of hMO development they suggested conducting a single-cell transcriptome analysis, as it has been shown before for cerebral organoids ([@B19]; [@B59]). In a recent study, single-cell transcriptomic data from hMOs demonstrated that there is an increased expression of neuronal- and stem cell-specific genes in 35 day- compared to 70 day-old hMOs, whereas exclusively the gene-gene correlations between only neuron-specific genes increased considerably at day 70 ([@B109]). This signifies an increasing commitment of cells toward the neuronal cellular fate during the course of organoid development and further supports the finding of a progressive maturation of post-mitotic neurons. The identification of these neuron-specific genes revealed that the genes up-regulated at the earlier time point are particularly relevant in the processes of neurogenesis, neuronal migration and differentiation \[for example, early B-cell factor 3 (EBF3) ([@B41]) and L1 cell adhesion molecule (L1CAM) ([@B92])\], whereas the up-regulated genes at the later time point have been implicated *in vivo* in a modulatory contribution to neurite extension \[for example, repulsive guidance molecule B (RGMB), [@B75]\]. This indicates a higher commitment of the cells toward their intended fate and a progressive maturation of post-mitotic neurons within the hMOs. Since the presence of neuronal subtypes, glutamatergic and GABAergic neurons have been reported in hMOs before ([@B116]; [@B57]), the residence of specific neuronal subtypes has been addressed with the high-resolution single-cell analysis ([@B109]). The expression of genes typical for dopaminergic, glutamatergic, GABAergic, and serotonergic neurons have been investigated and their presence further confirmed by immunohistochemistry staining for the respective neurotransmitters. This allows dopaminergic, glutamatergic and GABAergic neurons and a few serotonergic neurons to be robustly detected within hMOs ([Table 2](#T2){ref-type="table"}). So far, detailed analysis of the neuronal subtype's function and their interaction has not been addressed. However, with regards to the fact that mDANs physiologically synapse in the striatum and not in the midbrain *in vivo*, hMOs are potentially limited as an *in vitro* model in this case.

Besides the detailed characterization of the neuronal population, also the analysis of astroglia and oligodendrocyte differentiation is also crucial for accurately modeling the human midbrain. The presence of astrocytes is essential for the formation of synapses and regular neuronal activity ([@B24]). Astrocytes are defined later than neurons during development, and their immunoreactivity is only detectable in hMOs after 35 days of cultivation ([@B82]; [@B20]; [@B83]; [Table 2](#T2){ref-type="table"}). Fast information transmission between neurons depends on axonal myelination, which is achieved by oligodendrocytes in the CNS. In most stem cell-based differentiation protocols, the differentiation into oligodendrocytes is extremely inefficient ([@B54]; [@B14]). However, differentiation into oligodendrocytes and detected myelination of non- dopaminergic neurons has been achieved in hMOs ([@B83]). Some neurites in these hMOs were ensheathed by oligodendrocytes and even structures such as the nodes of Ranvier became apparent, which are of critical importance for electrochemical transmission of signals in axons ([@B37]). The feature of unmyelinated or thinly myelinated neurons is particularly well described for SNc mDANs, and explains why only about 30% of βIII Tubulin (TUJ1) and myelin basic protein (MBP) overlapping cells have been quantified in the hMO system ([@B12]; [@B88]; [@B113]; [@B83]). To allow for future applications and improve the impact of hMOs in pathophysiological and pharmacological studies, the electrical activity and functional maturity of the midbrain-specific 3D cultures have been assessed. The presence or rather the co-localization of the presynaptic marker SYNAPTOPHYSIN and the postsynaptic marker PSD95 indicated direct contact between a pre- and a postsynapse ([@B83]). The exact morphology of hMO-derived synapses until now has not been addressed in detail, although other hPSC-derived brain organoids already reflect many aspects of human synapse formation and function ([@B121]). Whole-cell patch recordings have been performed with sliced hMOs sections ([@B57]) or with neurons obtained from hMOs ([@B110]). This is an established, but invasive method that allow specific neuronal subtypes to be identified and analyzed, however, the continuous development of an individual organoid cannot yet be followed in such detail. Alternatively, non-invasive recordings of extra cellular field potentials can be achieved by a MEA systems and allow insights into physiological properties of *in vitro* cultures and chronological analysis ([@B74]). [@B116] detected spontaneous and evoked electrophysiological activities in their ENTs. Furthermore, in the study of [@B83] spikes occurred closely in time on multiple electrodes, which indicates neuronal network synchronicity, were detected. To specifically determine the activity of different neuronal receptors within the organoid, the response to chemical compounds can be examined. The functionality of DA receptors has been tested with the application of quinpirole, a specific D2/D3 receptor agonist. Importantly, mDANs express D2 autoreceptors. This has previously been used in several studies and shown to effectively suppress the firing in hMOs ([@B57]; [@B83]; [@B109]). Together with the reported DA production and release, this strongly suggests that TH-positive neurons, developed in hMOs, exhibit electrophysiological and biochemical qualities of mature mDANs and express functional, quinpirole-responsive, DA receptors. To further isolate and attribute the recorded signals to neuronal subtypes, inhibitory and excitatory communication was additionally blocked with specific drugs following an established experimental design by [@B53]. Drugs like, Gabazine an antagonist of GABA receptors which result in a disinhibition of target neurons of GABAergic neurons, as well as NMDA-receptor and AMPA/Kainate-receptor antagonists inhibiting glutamatergic excitatory communication were used ([@B53]). Together with the characteristic hallmarks of synapse formation, consisting of a direct contact between pre- and postsynapses and composing the prerequisite for electrophysiological and neuronal network functionality, these experiments confirmed functional GABAergic and glutamatergic neurons within the hMOs, in addition to the functional DA receptors present. While neurons do not exist in isolation in the CNS but rather form functional networks with other neurons and non-neuronal cells, it is important to expand our research of neurodegenerative diseases using 3D models that are able to recapitulate cell autonomous as well as non-cell autonomous aspects. Utilizing 3D cell culture models that comprise a variety of neuronal subtypes could lead to new insights into the selective vulnerability, which is observed in neurodegeneration. Evidence suggests that specific regulation of the excitability of mDANs by other neuronal subtypes in the midbrain might explain their selective vulnerability in PD ([@B66]; [@B18]; [@B17]). This underlines the importance and the enormous potential for future disease models that utilize hMOs, as they contain functionally connected heterogeneous neuronal populations.

Disease Modeling in Midbrain-Specific Organoids {#S7}
===============================================

Organoids, specifically modeling the human midbrain, hold great promises for studying the human brain development and for modeling the neurodegenerative disorder PD. PD is the second most common degenerative neurological disorder after AD and is defined by the selective loss of mDANs in the SNc of the human midbrain. Intriguingly, after decades of research on PD, the molecular mechanisms underlying the initiation and progression of the neurodegenerative disease, commonly occurring as idiopathic form, have not been entirely revealed and remain largely elusive ([@B99]). Therefore, the establishment of region-specific brain organoids offers new possibilities to study neuronal diseases that are linked to a specific part of the human brain, such as PD. Neurodegenerative disorders, such as PD, are typically considered to be age-associated diseases ([@B106]; [@B122]). However, there is accumulating evidence that PD has a strong neurodevelopmental component that probably defines the susceptibility to develop the disease ([@B42]; [@B72]; [@B104]). This finding supports the importance of human brain development models to investigate the disease's underlying mechanisms. A recent publication provides a proof-of-principle study where either patient-derived or genetically modified hMOs harboring the disease-associated G2019S mutation in the *LRRK2* gene show PD-relevant phenotypes including reduced number of mDANs ([@B110]). By evaluating the number of links (branching) and nodes (dendrite bifurcation points) of the mDANs developed within the different hMO groups, a significant reduction of the dopaminergic network complexity in the patient-derived TH-positive neurons was identified which is also known to occur in PD patients' brain ([@B7]; [@B65]; [@B110]). Based on another published hMO protocol, [@B62] also derived organoids carrying the *LRRK2*-G2019S mutation ([@B57]). In line with the findings of [@B110] and [@B62] discovered that the mDANs within the *LRRK2*-G2019S organoids reveal a decreased neurite length in comparison to the mDANs within the control organoids. They further assessed an overall decreased expression level of mDANs-specific markers, such as TH, aromatic l-amino acid decarboxylase (AADC), and DAT in their engineered *LRRK2*-G2019S hMOs ([@B62]). They achieved a partial recovery of those gene's expression levels after treating the *LRRK2*-G2019S mutant organoids with the *LRRK2* kinase inhibitor GSK2578215A. This *LRRK2* inhibition suggests a positive impact on mDAN cell death and additionally proves that this 3D cell culture system is susceptible to investigating therapeutic strategies against PD ([@B62]). [@B62] also determined hMOs carrying the *LRRK2*-G2019S mutation exhibit an abnormal localization of α-synuclein that is phosphorylated at serine 129 (pS129). They claim that pS129-α-synuclein is aberrantly expressed in mutated hMOs and they detected a *LRRK2*-G2019S mutation-dependent increase of thioflavin T-positive deposits in TH-positive neurons over time, even though the overall α-synuclein expression did not appear to increase ([@B62]). Surprisingly, these detected thioflavin T-positive deposits appeared to be extracellular and were not clearly overlapping with the TH signal. Whether these findings are reproducible with another analytical method, still needs to be explored further. Nevertheless, the assessment of PD-associated pathologies, such as the synucleinopathies, in human-specific advanced cell culture models is crucial due to the inherent differences between human and mouse mDAN vulnerability and as existing murine transgenic models have not been efficient in developing an accurate representation of the underlying disease mechanisms ([@B16]; [@B15]; [@B49]; [@B64]). In the study of [@B110] a significant increase of FOXA2-positive progenitor cells in the patient-specific organoids was demonstrated. Since FOXA2 is required for the generation of mDANs, it is hypothesized that this might be a compensatory response to an impaired specification of mDANs promoted by the mutated *LRRK2* gene ([@B102]), additionally it might be a results of a decreased differentiation potential of the progenitor cells. Similar compensatory mechanisms have been described in PD before and might represent an attempt to counteract neurodevelopmental defects induced by PD-specific mutations ([@B9]). While introducing also isogenic control hMOs, it was also confirmed that the introduction of the *LRRK2*-G2019S mutation caused deleterious effects on the complexity of mDANs within a healthy background. On the contrary, *LRRK2*-G2019S gene correction within a PD patient background is not sufficient to rescue this effect. As *LRRK2*-G2019S is not fully penetrant and the probability of developing PD individually varies among the carriers, it is suggested that its pathological function comprises of additional pathways ([@B108]; [@B44]). In this context, a permissive genetic background, due to cumulative genetic variants, might mediate and either enhance or diminish the *LRRK2*-induced neurodegeneration ([@B10]). Remarkably, in the analysis of all studied features, the PD patient-derived lines cluster together, independently of the presence or absence of the mutation ([@B110]). This indicates that the genetic background of the PD patients, regardless of gene editing, accounts for most of the differences between the studied cell lines and seems to be a major discriminating factor. Thus, not the *LRRK2*-G2019S mutation but rather the genetic background of the patients constitutes the strongest contribution to the phenotypes and supports the hypothesis that the genetic background of PD patients can influence the degeneration of mDANs ([@B10]). These findings show that 3D hMOs and the corresponding mDANs represent powerful new tools for *in vitro* disease modeling. Importantly, in PD patients in the midbrain mainly the SN is affected while a neighboring region, the ventral tegmental area, which also contains DNs is largely unaffected. Current hMO models so far have not addressed this different vulnerability sufficiently. However, this is a limitation that certainly will be investigated in the future.

By deriving further hMOs that carry defects in genes that are known to cause PD we could broaden the understanding of disease-related abnormalities and the context in which they arise ([@B5]). The patient-specific nature of these models also opens promising avenues for future personalized medicine approaches ([@B13]; [@B50]; [@B110]).

Perspectives {#S8}
============

The generation and characterization of midbrain-specific organoid protocols and thereby the provision of sophisticated *in vitro* models to study both neurodevelopmental processes and neurodegenerative diseases of the human midbrain have led to novel findings in the field of advanced 3D *in vitro* cell culture systems. Furthermore, the reported PD-relevant phenotypes in PD patient-derived hMOs have proved that these methods are a powerful tool for human-specific *in vitro* disease modeling of neurological disorders.

For such applications, an organoid model should be reproducible and stable for extended cultivation and manipulation. Even though the organoid technology is a powerful asset in the field of brain research, the hMO models show intrinsic disadvantages and limitations ([@B6]; [@B119]). The lack of a natural body axis or supportive tissue prevents an organoid's organization that is identical to the pattern of the *in vivo* human brain ([@B71]; [@B60]; [@B119]). The identification of a specific brain regions as well as the reproducibility might be imperfect, nevertheless it is unlikely to create the exact culture conditions found in the human brain *in utero* ([@B117]). A major limitation of the hMOs presented here, as well as other published brain organoid systems, is the absence of vasculature, which restricts the supply of oxygen and nutrition, especially in the inner part of the organoids ([@B60]; [@B119]). It also might limit the growth of organoids beyond a certain size and increase the appearance of dead cells in the center of the organoids ([@B43]; [@B83]; [@B6]). The cell number, and consequently the cell density within the organoid seem to play an important role and might be a target for improvement. The choice of the surrogate matrix, the starting point and duration of the differentiation are further aspects that can influence the fidelity of the 3D culture. Recently, brain organoids were successfully transplanted into a mouse brain and murine blood vessels could be detected in the grafts ([@B76]). Even though the transplanted organoid mimicked more precisely the *in vivo* brain anatomy, this method bears the disadvantage of xenocontamination ([@B117]; [@B119]). The absence of microglia, the resident innate immune cells of the CNS, is another major disadvantage for disease modeling, as they are actively involved in the development and maturation of neurons. In the case of cerebral organoids, an adaptation for a microglia-containing organoid model has been recently published ([@B89]). Since some hMOs are derived from the neuroectoderm and microglia originate developmentally from the mesoderm, there is only the possibility to integrate externally derived microglia or their precursors to the developing hMO ([@B84]; [@B3]; [@B46]; [@B117]; [@B119]).

Future development of cell culture technologies will further improve brain-specific organoid models and will support both the investigation of more complicated interactions in the human brain and the modeling of a larger range of neurological disorders ([@B33]; [@B119]). Despite the current limitations, we can conclude that the hMO system presented here, along with other models, may be a first step toward a more human patient-specific, probably even personalized, era of advanced disease modeling and therapy development.
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